Form Type:  SC 13G/A
Filing Date:  7/11/2022 
CIK:  0001377121 
Address:  7707 GATEWAY BLVD., SUITE 140 
City, State, Zip:  NEWARK, California 94560-1160 
Telephone:  (510) 474-0170 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
0.00 (0.00%)  
Trade Time: 
Nov 25  
Market Cap: 
Trade PTGX now with 

© 2022  
Description of Business
We are a biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development, all derived from the Company's proprietary technology platform. Our clinical programs address two broad categories of diseases; (i) hematology and blood disorders, and (ii) inflammatory and immunomodulatory diseases. Figure 1: Our Product Pipeline [[Image Removed: Graphical user interface, application Description automatically generated]] Our most advanced clinical asset, rusfertide (generic name for PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of erythrocytosis, iron overload and other blood disorders. Hepcidin is a key hormone in regulating iron equilibrium and is critical to the proper development of red blood cells. Rusfertide mimics the effect of the natural hormone hepcidin, but with greater potency, solubility and stability.
Register and access this filing in: